The major types of non-small-cell lung cancer (NSCLC)-squamous cell carcinoma and adenocarcinoma-have distinct immune microenvironments.
SUMMARY
The major types of non-small-cell lung cancer (NSCLC)-squamous cell carcinoma and adenocarcinoma-have distinct immune microenvironments. We developed a genetic model of squamous NSCLC on the basis of overexpression of the transcription factor Sox2, which specifies lung basal cell fate, and loss of the tumor suppressor Lkb1 (SL mice). SL tumors recapitulated gene-expression and immuneinfiltrate features of human squamous NSCLC; such features included enrichment of tumor-associated neutrophils (TANs) and decreased expression of NKX2-1, a transcriptional regulator that specifies alveolar cell fate. In Kras-driven adenocarcinomas, mis-expression of Sox2 or loss of Nkx2-1 led to TAN recruitment. TAN recruitment involved SOX2-mediated production of the chemokine CXCL5. Deletion of Nkx2-1 in SL mice (SNL) revealed that NKX2-1 suppresses SOX2-driven squamous tumorigenesis by repressing adeno-to-squamous transdifferentiation. Depletion of TANs in SNL mice reduced squamous tumors, suggesting that TANs foster squamous cell fate. Thus, lineage-defining transcription factors determine the tumor immune microenvironment, which in turn might impact the nature of the tumor.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) represents approximately 85% of all lung cancers and predominantly comprises lung squamous-cell carcinoma (LSCC) and adenocarcinoma (LADC). LSCC and LADC can be distinguished by their histopathology, biomarkers, patterns of gene expression, genomic alterations, and response to therapy (Campbell et al., 2016; Langer et al., 2016) . Adenosquamous carcinoma is a less common NSCLC variant defined by the presence of both LADC and LSCC components. Recently, it has been shown that LADC and LSCC have differences in the immune microenvironment (Kargl et al., 2017; Nagaraj et al., 2017; Xu et al., 2014) . This is clinically relevant because advances in immunotherapy have led to the approval of immune checkpoint inhibitors for NSCLC (Ribas and Wolchok, 2018) . Immunotherapy response is impacted by the complex and dynamic interactions among multiple immune cell types and cancer cells in the tumor immune microenvironment (TIME) (Pitt et al., 2016) . It is important to decipher the function of cells in the TIME to better understand the role of the immune system in tumor initiation and progression and to fully exploit the potential of immunotherapy.
Neutrophils are among the first responders to infection and tissue damage (Powell and Huttenlocher, 2016) . Neutrophils are present in the TIME of most solid tumors and can contribute to tumor progression by promoting cell growth, angiogenesis, metastasis, and immune evasion, although they can play anti-tumor roles as well (Coffelt et al., 2016; Powell and Huttenlocher, 2016) . A pan-cancer study of 25 malignancies, including NSCLC, showed that neutrophil abundance in the TIME is a leading predictor of a poor outcome (Gentles et al., 2015) . Similarly, a high neutrophil-to-lymphocyte ratio is associated with poor prognosis in many solid tumors, including NSCLC (Templeton et al., 2014) . Mice that bear activating mutations in Kras and that are deficient for the tumor suppressor Lkb1 (Kras LSL-G12D/+ ;Lkb1 fl/fl [KL mice]) harbor a spectrum of NSCLC histologies, and tumor-associated neutrophils (TANs) in this model demonstrate pro-tumor features (Koyama et al., 2016; Nagaraj et al., 2017) . Neutrophils are more abundant in human LSCC than in LADC, whereas macrophages are more abundant in LADC (Eruslanov et al., 2014; Kargl et al., 2017) . TAN enrichment in LSCC is also observed in genetically engineered mouse models (GEMMs); LSCCs in Lkb1 fl/fl ;Pten fl/fl (LP) and Sox2 LSL/LSL ;Pten fl/fl ; Cdkn2ab fl/fl (Sox2PC) mice have more neutrophils but fewer macrophages than LADC GEMMs (Ferone et al., 2016; Xu et al., 2014) . Similarly, adenosquamous tumors in KL mice have more TANs and fewer macrophages than adenocarcinomas in the same genetic model (Nagaraj et al., 2017) . On the basis of this result, it was hypothesized that squamous histological classification (i.e., histotype) rather than genetic alterations (i.e., genotype) determine the immune contexture (Nagaraj et al., 2017) . Tumor histology and genetic alterations are intimately linked in NSCLC, so it is difficult to tease apart whether histotype or genotype is the most important determinant of the TIME. A significant subset of lung tumors (so-called ''not otherwise specified'' tumors) is difficult to classify histologically, and both tumor heterogeneity and plasticity, including changes in tumor subtype in response to targeted therapy, occur in the clinical setting. Therefore, it is important to determine whether and how histotype and/ or genotype dictate the immune microenvironment. Specifically, it remains unknown which factors promote the difference in TAN levels between LSCC and LADC. During development, the transcription factors SOX2 and NKX2-1 exhibit opposing patterns of expression within the primitive foregut and embryonic lung (Morrisey and Hogan, 2010) . Likewise, in the adult lung, SOX2 amounts are highest in the proximal airways, whereas NKX2-1 amounts are highest in type 2 pneumocytes of the alveoli. In the normal lung, SOX2 promotes proliferation and maintains stem and basal cell identity, whereas NKX2-1 specifies alveolar cell identity. SOX2 and NKX2-1 exhibit opposing patterns of expression in the two major subtypes of NSCLC as well. SOX2 is amplified in $21% and overexpressed in >80% of LSCCs, whereas it is rarely expressed in LADC (Campbell et al., 2016) . In contrast, NKX2-1 is amplified in $10% and highly expressed in 70%-80% of LADC and is rarely expressed in LSCC (Campbell et al., 2016) . LADC shares features with normal alveolar cells where NKX2-1 is normally expressed, whereas LSCC shares features of basal cells where SOX2 is normally expressed. SOX2 is thus considered a lineage-specific oncogene because it drives multiple squamous cancers, including lung cancer, and directs tumor type toward a basal-cell fate (Bass et al., 2009; Ferone et al., 2016; Lu et al., 2010; Mukhopadhyay et al., 2014) . On the other hand, the impact of NKX2-1 in LADC appears to be context dependent. NKX2-1 is considered to be a lineage-specific oncogene in adenocarcinoma when it is amplified or highly expressed (Tanaka et al., 2007) . However, a subset of adenocarcinomas is NKX2-1 negative, and these tumors are associated with poor prognosis relative to NKX2-1 + adenocarcinomas. Furthermore, loss of NKX2-1 accelerates Kras mutant lung adenocarcinoma in mice and alters their cell fate, suggesting that NKX2-1 has lineage-specific tumor suppressor functions as well. Here, we developed and employed multiple GEMMs to elucidate the role of lung-cancer lineage specifiers SOX2 and NKX2-1 in tumor cell fate and neutrophil recruitment. Figure S1B ).
RESULTS

Murine
GFP and SOX2 expression were induced in MEFs infected with adenoviruses that express Cre recombinase under the control of a CMV promoter (Ad5-CMV-Cre), and Sox2 homozygous cells expressed both proteins at higher levels than heterozygous cells ( Figures S1C and S1D ). Next, we infected homozygous and heterozygous SL mice, LP mice, and Kras LSL-G12D/+ ;Trp53 fl/fl (KP) mice with Ad5-CMV-Cre by using intranasal inhalation. Although heterozygous SL mice had not developed tumors one year after infection, homozygous SL mice developed tumors after an average of 11 months, comparable to the latency of other LSCC GEMMs (Ferone et al., 2016; Xu et al., 2014) (Figures S1E and S1F). Tumor penetrance was higher in SL mice than Lenti-Sox2-Cre-infected Lkb1 fl/fl mice (71% versus 40%) and slightly higher than that of LP mice (60%) ( Figure S1G ). SL mice developed one or a few tumors, in similarity to the LP model ( Figure S1H ), and were GFP positive as revealed by whole-mount microscopy ( Figure S1I ). The vast majority (>90%) of tumors in the SL mice were classified as squamous by two board-certified pathologists (B.L.W. and E.L.S.), whereas smaller LADCs were rarely detected in the same animals ( Figure 1A and Figure S1J ). With flattened and keratinized cells and desmoplastic stroma, SL tumors exhibited characteristic features of squamous tumors and were similar to human LSCC and murine LP tumors ( Figure 1A ). SL tumors were positive for two established LSCC biomarkers, KRT5 and DNp63 ( Figures 1B-1D ). Mutations in components of the PI3K-AKT-mTOR pathway result in activation of this signaling axis in $47% of LSCCs (Campbell et al., 2016) . LKB1 functions as a tumor suppressor through its negative regulation of the mTOR pathway. LKB1 loss-of-function alterations are relatively infrequent in human LSCC but are found in a significant fraction of adenosquamous tumors (Zhang et al., 2017) . We assessed mouse and human LSCC for phosphorylated 4EBP1 (p4EBP1), an established marker of mTOR pathway activation. SL tumors were positive for SOX2 and p4EBP1 at protein amounts similar to those of LP and human LSCC ( Figures 1E-1G ). KP adenocarcinomas were negative for SOX2 and had low to no detectable p4EBP1. IHC analysis of 43 human LSCCs demonstrated that 58% of samples were positive for p4EBP1 and that 93% were positive for SOX2 (58% were positive for both), suggesting that murine SL tumors resemble a significant fraction of human LSCCs (Figures 1H and 1I) . Together, these results demonstrate that the combination of SOX2 overexpression and mTOR pathway activation, frequent characteristics of human LSCC, promotes LSCC tumorigenesis.
Murine SOX2-Driven Lung Squamous Tumors Recapitulate the Molecular Phenotype of Human LSCC To determine whether SL tumors recapitulate the molecular features of human LSCC, we compared gene expression profiles of SL, LP, and KP mouse tumors to normal adult mouse lung and human LSCC by RNA sequencing (RNA-seq). Cross-species analysis of differentially expressed genes demonstrated Error bars indicate mean ± SEM. Two-tailed unpaired t tests, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant. In (C), (D), (F), and (G), each dot represents one tumor from 3-8 mice per genotype and six patient tumors. See also Figure S1 . (legend continued on next page) similarities among SL, LP, and human LSCC (Figure 2A ). Mouse and human squamous tumors aligned more closely in a semi-unsupervised clustering analysis and were distinct from KP adenocarcinomas and normal lung tissue. Expression of squamous biomarkers such as Krt5, Krt14, and other cytokeratin genes, as well as Trp63 and Sox2, was significantly increased in SL tumors, whereas expression of adenocarcinoma markers such as Nkx2-1, Sftpc, and other surfactant genes was decreased (Figure 2B) . Gene-set enrichment analysis (GSEA) of human LSCC compared to LADC derived from The Cancer Genome Atlas (TCGA) revealed a significant positive enrichment for genes expressed in SL or LP versus KP tumors ( Figure 2C and Figure S2A ). There was a significant depletion of adenocarcinoma-enriched genes in SL and LP versus KP tumors ( Figures 2C and S2A ). Ingenuity pathway analysis (IPA) of differentially expressed genes in SL versus KP tumors identified human and mouse ''embryonic stem cell pluripotency'' pathways ( Figure S2B ). By GSEA, SL tumors and human LSCCs were enriched for gene sets, including genes in the DNp63 pathway, lung-stem-cell markers Zuo et al., 2015) , and tracheal basal-cell-surface markers (Figure S2C and Tables S2  and S3 ). Together, these findings suggest that SL tumors strongly recapitulate human LSCCs at the molecular level.
Mouse Lung Tumors Recapitulate the Human Tumor
Immune Microenvironment with Elevated Quantities of Tumor-Associated Neutrophils IPA identified ''granulocyte adhesion and diapedesis'' among the top enriched pathways in SL versus KP tumors ( Figure S2B ). It also identified multiple immune-related pathways, including those involving specific immune cell types, cytokines, and transcription factors as key upstream regulators ( Figures S2D and  S2E ), as significantly enriched in SL tumors, as compared to KP tumors. The comparison of all significantly enriched pathways in human LSCC versus LADC (Campbell et al., 2016) and in SL versus KP tumors demonstrated that there is a high degree of overlap of immune-related pathways between mouse and human LSCC ( Figure S2F ). GSEA also suggested that SL tumors are enriched for gene signatures of immune cells in lymphoid, myeloid, and macrophage lineages ( Figure S2G ). Compared to normal lung tissue and KP tumors, SL tumors had a significant positive enrichment for T cell, neutrophil, and TAN gene sets ( Figure 2D and Figure S2H ). Consistent with TAN enrichment in squamous tumors, we found that multiple upstream molecules associated with neutrophil recruitment and ''N2'' pro-tumor function were enriched in SL tumors ( Figure S2D ). Together, these findings suggested that LSCC and LADC have significantly different TIMEs.
In order to better understand the LSCC TIME, we analyzed the abundance of T cells in murine tumors. IHC for CD3 demonstrated significantly greater T cell infiltration in SL and LP tumors compared to KP adenocarcinomas ( Figure 2E ). High neutrophil infiltration in SL tumors was evident on H&E evaluation by a pathologist (E.L.S.) ( Figure S2I ) and was confirmed by IHC analysis of neutrophil markers CD11B, MPO, and LY6G ( Figure 2E ). Neutrophils were found in extravascular clusters located throughout the TIME; these clusters were found at the periphery and within the tumor, often immediately adjacent to the carcinoma cells. Because squamous tumors were apparently growing in this inflammatory and T-cell-rich microenvironment, we postulated that the cancer cells might employ immune evasion mechanisms. We found that FOXP3 + regulatory T (Treg) cells were enriched in SL tumors compared to LP and KP tumors ( Figure 2E ). SL tumors also displayed increased expression of genes encoding multiple immunosuppressive molecules such as Arg1, Vtcn1, Cd80, Btla, Havcr2, , as measured by RNA-seq; some of these molecules have increased gene expression in LP squamous tumors (Xu et al., 2014) (Figure 2F ). SL tumors showed reduced expression of major histocompatibility complex (MHC) genes (Figure 2F) , suggesting reduced antigen presentation as a potential immune evasion mechanism active in these tumors. Collectively, SL squamous tumors display some hallmarks of an immunosuppressive TIME, for example enrichment of Treg cells and TANs. This does not rule out the possibility that adenocarcinoma also harbors an immunosuppressive TIME, albeit potentially through distinct mechanisms.
SOX2 Promotes Tumor-Associated Neutrophil
Recruitment in the Absence of Squamous Transdifferentiation Recent studies suggest that elevated TANs in LSCC might be due to a squamous histotype as opposed to a genetic phenomenon (Nagaraj et al., 2017) . It is challenging to decouple the function of SOX2 from its role in ''squamousness'' because SOX2 can promote squamous differentiation (Bass et al., 2009; Lu et al., 2010; Mukhopadhyay et al., 2014) . To tease apart these functions, we overexpressed SOX2 in the KP adenocarcinoma model to determine whether SOX2 can alter tumor histotype and/or TAN levels. KP mice were infected with Lenti-Sox2-Cre or control Lenti-GFP-Cre viruses ( Figure 3A) , and lungs were harvested four months later. Lenti-GFP-Cre-infected KP tumors (KPG) were GFP positive ( Figure 3B ), as expected. We analyzed serial sections by IHC for squamous and neutrophil markers in matched individual tumors. In Lenti-Sox2-Cre-infected KP animals (KPS), SOX2 overexpression was observed in many but not all tumors, indicating an occasional uncoupling of SOX2 expression from Cre-mediated recombination ( Figures 3C and  3D ). All KPS tumors exhibited adenocarcinoma histology regardless of the amount of SOX2 ( Figure 3B Figure S2 and Figure 4G ). Together this suggests that SOX2 promotes a reduction in NKX2-1 amounts and/or activity. Although the mechanism of regulation is unclear, chromatin immunoprecipitation-RNA sequencing (ChIP-seq) analyses suggested that SOX2 and NKX2-1 can each bind their own promoters, and SOX2 might weakly bind the Nkx2-1 promoter ( Figure S3C ). Furthermore, inducible SOX2 expression can repress NKX2-1 amounts in four of five human lung cancer cell lines examined ( Figure S3D ). Because SOX2 promotes TAN recruitment and leads to decreased NKX2-1 activity, we tested whether NKX2-1 plays a role in TAN recruitment. We employed Kras FSF-G12D/+ ; Trp53
Frt/Frt ;Rosa26 FSF-CreERT2 ;Nkx2-1 fl/fl (KPN) mice, where Nkx2-1 can be temporally deleted in the KP adenocarcinoma model. We infected KPN mice with Ad5-CMV-Flp to initiate tumorigenesis, and 6 weeks after infection, we treated them with vehicle or tamoxifen to cause Nkx2-1 deletion. Four weeks after tamoxifen treatment, we harvested tumors for IHC analysis. KPN tumors exhibited a significant reduction in NKX2-1 and SPC expression in comparison to KP tumors, exhibited a mucinous adenocarcinoma histology (Figures 4H-4J) consistent with our prior studies (Snyder et al., 2013) , and did not express SOX2 ( Figures 4H and 4K ). However, Nkx2-1 deletion in KPN adenocarcinomas resulted in significantly elevated quantities of TANs Figure S3E ). Together, these results demonstrate that NKX2-1 suppresses TAN recruitment independently of SOX2 induction or squamous histotype.
SOX2 and NKX2-1 Inversely Regulate the Neutrophil Chemoattractant Cxcl5
We sought to define the mechanisms by which SOX2 and NKX2-1 regulate neutrophil recruitment. GSEA suggested that SL tumors are positively enriched for cytokine and chemokine signatures in comparison to KP tumors ( Figure S4A ). Expression of neutrophil-recruitment-associated genes such as Cxcl2, Cxcl3, Cxcl5, and Ppbp (Cxcl7) was greater in SL and LP tumors than in KP tumors ( Figure 5A ). We employed an unbiased comprehensive approach to determine whether SOX2 and NKX2-1 converge on the regulation of any of these chemokines. First, we identified SOX2 binding sites in the genomes of LP tumors and KPS cell lines by ChIP-seq. We chose LP tumors because they represent a neutrophil-rich squamous tumor with physiological levels of SOX2 expression, and we used KPS samples because they recapitulate SOX2 function in TAN recruitment independently of squamous histotype. To generate a similar dataset for NKX2-1 targets, we used published NKX2-1 ChIP-seq data from K adenocarcinomas and gene expression data comparing K and Kras LSL-G12D/+ ;Nkx2-1 fl/fl (KN) tumors (Snyder et al., 2013) . ChIP-seq analyses identified SOX2 and NKX2-1 binding motifs that were similar to those identified in previously published studies (Maeda et al., 2012; Watanabe et al., 2014) (Figure S4B ). SOX2 and NKX2-1 bound some of the same genes, whereas each factor also bound unique targets ( Figure 5B ). We integrated ChIP-seq and gene expression data for each dataset to identify genes that were bound by and transcriptionally activated or suppressed by SOX2 and NKX2-1. Genes that were transcriptionally regulated by both SOX2 and NKX2-1 were mostly regulated inversely ( Figure 5C ), such that SOX2-induced genes were repressed by NKX2-1 and such that NKX2-1-induced genes were suppressed by SOX2. In contrast, many fewer genes were induced (or repressed) by both SOX2 and NKX2-1. These data suggest that SOX2 and NKX2-1 have unique genomic targets and inversely regulate transcription of many genes in lung cancer.
SOX2 promotes TAN accumulation, whereas NKX2-1 inhibits neutrophil accumulation in tumors, so we focused on genes that were induced by SOX2 and/or repressed by NKX2-1. Cxcl5 was the only known neutrophil chemoattractant gene bound by either transcription factor in this category. Binding sites for both SOX2 and NKX2-1 could be identified in the promoter and first exon of Cxcl5 ( Figure 5D ). Cxcl5 mRNA expression was significantly elevated in SL and LP tumors compared to KP tumors and normal lung tissue, as well as in KN versus K tumors ( Figure S4C ). CXCL6, the human ortholog of mouse Cxcl5 ( Figures S4D and S4E ), was significantly elevated in human LSCC compared to LADC (Campbell et al., 2016) (Figure S4C) . CXCL6 was one of only two CXCR2 ligands that significantly correlated with a squamous subtype and high SOX2 and low NKX2-1 expression in a large collection of human NSCLC samples from TCGA (Figure 5E and Figures S4C and S4F) .
Consistent with the gene expression data, SOX2 + KPS tumors and KPN tumors had significantly higher CXCL5 protein levels than control SOX2 À KPS, KPG, and KP tumors (Figures 5F and 5G). Moreover, SL and LP squamous tumors had high levels of CXCL5, whereas KP adenocarcinomas completely lacked it. Together, these findings suggest that SOX2 and NKX2-1 inversely regulate Cxcl5 expression. To further test this, we overexpressed SOX2 in a panel of human lung cancer cell lines. Exogenous SOX2 was sufficient to induce CXCL6 in five of six cell lines ( Figure S4G ). In contrast, altering NKX2-1 amounts by overexpression or CRISPR-mediated loss was not sufficient to alter CXCL5 or CXCL6 levels in vitro ( Figures S4H and S4I ).
Thus, it appears that NKX2-1 regulation of CXCL6 differs in vitro in human cells compared to mouse tumors. To determine whether CXCL5 expression is sufficient to promote neutrophil recruitment, we infected KP mice with Lenti-Cxcl5-Cre or Lenti-GFP-Cre viruses and analyzed lungs 3-4 months after infection. Reminiscent of our observations with Lenti-Sox2-Cre, there was an occasional uncoupling of Cre and CXCL5 expression; some tumors lacked high CXCL5 expression ( Figure 5H ). KP-CXCL5 + (KPC5) tumors demonstrated high expression of CXCL5 and a significant increase in TAN accumulation ( Figure 5H ). When tumors with and without CXCL5 were detected near each other in the KPS or KPC5 models, only CXCL5 + tumors harbored neutrophils-suggesting that CXCL5 0 s impact on neutrophil recruitment is relatively local ( Figure S4J ). These data demonstrate that tumor-derived CXCL5 expression is sufficient to promote TAN accumulation in lung cancer.
Loss of NKX2-1 Dramatically Accelerates Squamous Lung Tumorigenesis
To better understand the functions of SOX2 and NKX2-1, we performed pathway analyses by using Enrichr on genomic targets that were transcriptionally regulated in vivo ( Figure 5C and Table  S4 ). SOX2 induced expression of its own target genes, as well as genes bound by the transcriptional regulators TP63 and NFE2L2, which are known oncogenic transcription factors in LSCC (Campbell et al., 2016) . SOX2-induced genes included those related to squamous cell fate (Krt6a and Krt19), ciliated cell fate (Foxj1), and the TP63 target gene (Perp) (Table S4 and Figure S5A) . SOX2-repressed genes overlapped with genes bound by chromatin regulators, including EZH2, which is enriched in squamous lung tumors (Zhang et al., 2017) . SOX2-repressed genes included gastric-and liver-fate regulators such as Hnf4a, Foxa2, and Vil1 (Maeda et al., 2012) . In contrast, NKX2-1 positively regulated genes involved in lung and alveolar cell fate; such genes included Sftpa1, Stfpb, and Sftpc. NKX2-1 inhibited expression of genes involved in gastrointestinal differentiation, consistent with our previous findings (Snyder et al., 2013) . NKX2-1-repressed genes overlapped with known SOX2 genomic targets, as well as gastrointestinal-cell-fate genes, including Foxa1, Perp, Lgals2, Lgals4, Krt20, Vil1, Cdh17 , and the mucous metaplasia gene, Spdef ( Figure S5A and Table S4 ).
SL tumors have reduced but not completely absent NKX2-1 expression, whereas human LSCCs tend to be completely negative ( Figure 4E ). Given that NKX2-1 repressed the expression of genes that are induced by SOX2, we speculated that complete loss of NKX2-1 might facilitate SOX2-driven tumorigenesis. To address this hypothesis, we generated Rosa26 LSL-Sox2-IRES-GFP ;
Nkx2-1 fl/fl ;Lkb1 fl/fl (SNL) mice. We infected SNL and SL mice with Ad5-CMV-Cre by using intratracheal inhalation and monitored mice for tumor formation via microCT imaging. We observed tumors in SNL mice as early as 8 weeks after tumor initiation ( Figure S5B ). We then subjected a large cohort of mice to histopathologic review 16 weeks after infection. All SNL mice (n = 10) harbored multifocal neoplasia, including mucinous adenocarcinomas and adenosquamous and squamous cell carcinomas ( Figures 6A and 6B and Figure S5C ). In contrast, only one SL mouse (n = 25) harbored a single LSCC at this time point. In SNL mice, both mucinous and squamous components expressed SOX2 and GFP and lacked NKX2-1 (Figure 6B and Figure S5D ). SOX2 intensity was heterogeneous in the squamous lesions, and basal-like cells expressed higher protein amounts than more highly keratinized tumor cells. SOX2 amounts were uniformly high in adenocarcinoma components, in concordance with a similar observation in KL mice (Zhang et al., 2017) . DNp63 and KRT5 were robustly expressed in the squamous components of the SNL tumors and were absent in the mucinous adenocarcinoma cells, which instead expressed gastric-differentiation markers, including HNF4A, LGALS4, and CTSE ( Figure 6B and Figure S5D ). This is consistent with our previous work showing that NKX2-1 loss leads to activation of a gastric-differentiation program in LADC (Snyder et al., 2013) . Adenocarcinomas arising in KL mice undergo transdifferentiation to a squamous differentiation state over time (Li et al., 2015) . To determine whether a similar phenomenon occurs in SNL mice, we analyzed lung tumors 4, 8, and 12 weeks after infection. At four weeks, we identified multifocal mucinous adenocarcinoma in the lungs of all mice (n = 6), whereas we found DNp63 + tumor cells only in a minority (33%) of mice ( Figure 6C ). The proportion of mice with DNp63 + tumor cells increased over time, such that by 12 weeks after infection DNp63 + tumor cells could be identified in the lungs of all SNL mice. The relative quantity of DNp63 + tumors in each mouse increased over time as well ( Figure 6D ). Taken together, these data show that loss of NKX2-1 dramatically accelerates tumorigenesis driven by SOX2 and loss of LKB1. These data suggest that alteration of these three genes induces mostly if not entirely mucinous adenocarcinoma lesions that undergo transdifferentiation to LSCC over time.
We sought to utilize this LSCC model to further investigate TAN regulation. TANs were abundant in all SNL tumors, regardless of histotype, although squamous tumors had subtly but significantly higher quantities of CD11B-and LY6G-positive cells ( Figures 6E and 6F ). Flow cytometry from SNL and KP tumors confirmed that squamous tumors exhibit increased TANs but fewer macrophages than do adenocarcinomas (Figures 6G and 6H and Figures S5E and S5F) . SNL tumors with squamous and adenocarcinoma histotypes both exhibited high CXCL5 The scale bars represent 50 mm. Error bars indicate mean ± SEM. Two-tailed unpaired t tests, ****p < 0.0001, **p < 0.01, *p < 0.05, ns = not significant. In (G) and (H), each dot represents one tumor from three to six mice per genotype. See also Figure S4 and Table S4 . Scale bars represent 50 mm. Error bars indicate mean ± SEM. Two-tailed unpaired t tests, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant. See also Figure S5 . (legend continued on next page) protein amounts ( Figures 6E and 6F) . Furthermore, $80% of SNL tumor cells expressed CXCL5, whereas < 10% of CD45 + immune cells from tumor-bearing or normal lungs expressed CXCL5 ( Figure 6I and Figure S5G ). TANs within both SNL LADC and LSCC tumor regions expressed CXCR2, the receptor for CXCL5 ( Figures 6J and Figures S5H and S5I) . Together, these findings suggest that CXCL5-expressing tumor cells recruit CXCR2 + neutrophils through a paracrine mechanism. They further suggest that TAN recruitment to tumors is determined by transcriptional regulators that specify cell fate.
TANs Exhibit Pro-tumor Features and Promote Squamous Tumors
To further characterize TANs in this model, we sorted CD45 + CD11B
+ GR1 + cells and examined their cytology ( Figure S6A ).
Many TANs exhibited a circular banding phenotype reminiscent of N2 TANs (Fridlender et al., 2009 Figure 7A and Figure S6B ). SiglecF + neutrophils exhibit multiple pro-tumor functions, including increased reactive oxygen species (ROS) production and the ability to foster tumor progression . To determine whether SNL TANs exhibit pro-tumor functions, we measured the ability of normal neutrophils (NNs) from healthy control lungs, PBNs, and TANs to produce intracellular ROS. TANs exhibited significantly more ROS than both NNs and PBNs by $3-to 4-fold ( Figure 7B and Figure S6C ). Because TANs exhibited cytological heterogeneity and only a subset expressed SiglecF, we sought to explore TAN heterogeneity by using single-cell RNA-seq (scRNA-seq). We sorted CD45 + CD11B + LY6G + cells from the peripheral blood of tumorbearing SNL animals (i.e., PBNs) or lung tumors (i.e., TANs) from the same animals ( Figure S6D ). We used the Chromium drop-seq platform (10x Genomics) to obtain transcriptomes from PBNs (n = 1744 cells) or TANs (n = 519 cells). We visualized chromium-derived transcriptional profiles by using t-distributed stochastic neighbor embedding (tSNE) (van der Maaten and Hinton, 2008). Cell Ranger clustering called nine distinct clusters, seven within the PBNs and two among the TANs ( Figure 7C ). Cxcr2 and house-keeping genes Actb and B2m were expressed in most clusters, regardless of the source of neutrophil. Although clusters 8 and 9 were negative for Cxcr2, they expressed S100a8/9, suggesting that these cells were also neutrophils (Figure S6E) . Consistent with the flow-cytometry data, SiglecF expression was largely confined to the TAN clusters ( Figure 7C ). GSEA revealed enrichment of the SiglecF-high versus SiglecFlow neutrophil gene signature in the SNL TAN population ( Figure S6F ). Furthermore, many N2-neutrophil-associated genes, such as Arg1, Ccl3, Ccl4 and Csf1, had significantly increased expression in TANs versus PBNs ( Figures  7C and 7D ). Pathway analyses using Enrichr on differentially expressed genes among TANs versus PBNs ( Figure 7D and Table S5) revealed that TANs had increased expression of genes involved in ROS and reactive nitrogen species (RNS) production, extracellular matrix (ECM) degradation, and N2-related chemokine signaling ( Figure 7E ). Neutrophil degranulation genes were differentially expressed among PBNs and TANs, and PBNs were enriched for pathways related to ''positive regulation of the immune system'' ( Figures S6E and S6G) . Together, these data suggest that LSCC TANs are a heterogeneous population in which at least some cells exhibit gene expression and functional activities ascribed to N2 TANs.
Finally, we sought to determine the function of TANs in the SNL model by using a neutrophil-depletion strategy (Fridlender et al., 2009; Steele et al., 2016) . SNL mice were treated with control or anti-LY6G antibody for three weeks, after which tumor-bearing lungs were harvested. TANs were significantly reduced in anti-LY6G-treated animals as determined by IHC analyses ( Figures  7F and 7G ). The lungs of neutrophil-depleted animals had fewer squamous tumors upon inspection of H&E-stained sections. Consistent with this observation, neutrophil-depleted lungs had significantly fewer DNp63 + tumors than did controls ( Figures  7F and 7H ). These findings suggest that TANs promote squamous tumorigenesis and might directly or indirectly impact tumor-cell fate in this transdifferentiation model. Altogether, these data suggest that lineage-specifier genes impact the tumor immune microenvironment, and the immune microenvironment in turn might impact tumor phenotype.
DISCUSSION
A distinctive feature of the LSCC TIME compared to that of LADC is the enrichment of neutrophils. Multiple LSCC mouse models (LP, Sox2PC, and now SL and SNL) display elevated neutrophils in comparison to LADC GEMMs (KP and K). It was previously postulated that histotype determines the TIME in NSCLC. Abundant keratinization in squamous tumors, for example, can molecularly resemble a persistent wound accompanied by aberrant inflammation. On the other hand, a growing body of evidence suggests that cancer-cell-intrinsic factors also impact the TIME (Bezzi et al., 2018; Li et al., 2018) . STAT3 and NF-kB signaling have roles in inflammation and are elevated in LSCC compared to LADC (Mukhopadhyay et al., 2014; Xiao et al., 2013) . A recent finding that Egfr-and Kras-driven LADC mouse tumors have distinct lymphocyte compositions also suggests that oncogenic drivers might dictate the TIME (Busch et al., 2016) . Our findings here reveal tumor-intrinsic mechanisms whereby lineage-specific tumor drivers (SOX2 and NKX2-1) inversely regulate TAN accumulation.
(E) Gene expression heatmaps for genes implicated in ROS and RNS production; extracellular matrix (ECM) degradation and cysteine endopeptidase activity; and chemokine signaling. Gene sets were derived from Enrichr analyses. Cell cluster numbers are labeled below each column identified in Figure 7C . p < 0.05 and Log2FC > 1 were used as a cutoff. (F-H) Representative images of IHC for CXCR2, MPO, and DNp63 in SNL mice treated with anti-LY6G antibody versus anti-IgG1 control antibody thrice weekly for 3-4 weeks (n = 8 mice per group) (F) and IHC quantification for CXCR2 and MPO (G) and DNp63 (H). The scale bar represents 50 mm. In (A), (B) , and (G), error bars indicate mean ± SEM; two-tailed unpaired t tests, ****p < 0.0001, **p < 0.005, *p < 0.05. (H) Fisher's exact test (two-tailed), ****p < 0.0001. See also Figure S6 and Table S5 .
Multiple chemokines can act upon the CXCR2 neutrophil receptor to induce neutrophil chemotaxis (Zlotnik and Yoshie, 2012) . Cxcl3, -5, and -7 have greater expression in SL and LP tumors than in KP and K tumors. Although the exact mechanism of transcriptional regulation requires further study, unbiased ChIP and RNA-seq data from GEMM tumors revealed that Cxcl5 is a direct genomic target of SOX2 and NKX2-1. We found that SOX2 overexpression or NKX2-1 loss is sufficient to induce CXCL5 in tumor cells in vivo, and tumor-associated CXCL5 is sufficient to recruit TANs. It is likely that other neutrophil recruitment chemokines are indirectly regulated in these lung-cancer subtypes and might also be sufficient for TAN recruitment. Future studies employing Cxcl5 genetic deletion and/or antibody-mediated CXCL5 depletion will be necessary to determine whether CXCL5 is required for TAN recruitment. Our data suggest CXCL5 regulation is governed by lineage specifiers rather than tumor histotype because we observe CXCL5 expression and TAN influx in adenocarcinomas when either SOX2 or NKX2-1 is altered. These data are consistent with previous studies in KL mice, where TANs are enriched in LSCCs as opposed to LADCs. In the KL model, SOX2 and CXCL5 expression levels are both increased, whereas NKX2-1 levels are decreased during adeno-to-squamous transdifferentiation (Nagaraj et al., 2017; Zhang et al., 2017) , consistent with the mechanisms proposed here. CXCL6, the human ortholog of mouse Cxcl5, is positively correlated with SOX2 and negatively correlated with NKX2-1 expression in human NSCLC, suggesting the mechanisms described here most likely function in human tumors.
Importantly, we found that NKX2-1, which has pro-and antioncogenic activities in LADC, is a tumor suppressor in LSCC. In SL and LP mice, the peripheral location of squamous tumors and the detection of smaller adenosquamous lesions at early time points hinted that these tumors originate from distal lung epithelium. Studies in Sox2PC mice showed that in addition to basal cells, club cells and alveolar type 2 cells can give rise to squamous tumors (Ferone et al., 2016) . SOX2 overexpression (either genetically or naturally acquired during tumorigenesis) is common to all three squamous GEMMs. NKX2-1 levels are reduced in squamous GEMMs but are not entirely absent, in contrast to complete NKX2-1 loss in human LSCC. These findings suggest that squamous tumors in GEMMs are primarily initiated in distal epithelium and transdifferentiate to squamous fate over time, perhaps during their long latency. It seems likely that all LSCCs must downregulate NKX2-1 to adopt a squamous fate, whether they arise from basal cells in the proximal airway or in the distal lung, where peripheral-type LSCCs arise. Consistent with this hypothesis, Nkx2-1 deletion significantly accelerated LSCC development, and there was evidence of transdifferentiation. ChIP and RNA-seq data suggested that NKX2-1 repressed known SOX2 target genes, so we speculate that this provides a mechanism by which NKX2-1 loss facilitates SOX2-driven transformation. An independent study recently found that Sox2 expression and Nkx2-1 deletion in the mouse lung (i.e., SN) cooperate to promote squamous lung cancer and that NKX2-1 loss alters SOX2 occupancy in the genome (Tata et al., 2018) . Similar to our observations in SNL mice, SN cells in that study might transdifferentiate in organoid cultures, including in the absence of stromal cells. If confirmed in vivo, this might suggest that neutrophils promote squamous tumorigenesis but are not required for transdifferentiation. Future studies should address how SN and SNL tumor development might differ in terms of latency, tumor-cell fate, and the TIME. Although the Tata et al. study did not investigate the TIME, our data predict that SN tumors will have elevated CXCL5 and TANs, as in SNL mice. Tata et al. suggest that airway cells are more permissive than alveolar cells for squamous transformation, so additional studies are warranted to determine how the cell of origin impacts tumor cell fate upon Nkx2-1 loss.
Our scRNA-seq data suggest that TANs are fundamentally different from PBNs and acquire pro-tumor features such as increased ROS activity and elevated expression of genes that block T cell activity and promote ECM degradation. Because the scRNA-seq data presented here are limited to small numbers of cells, fully deciphering the molecular and functional heterogeneity among TANs will require further studies. The neutrophil depletion experiments demonstrated that TANs preferentially promote squamous tumors. This observation is intriguing because it suggests a bidirectional crosstalk between tumor cells and immune cells. The underlying mechanism by which TANs impact tumor cell fate remains elusive because TANs might either create a favorable TIME for preexisting squamous cancer cells over adenocarcinoma cells or accelerate adenoto-squamous transdifferentiation. Because ROS and hypoxia can promote adeno-to-squamous transdifferentiation (Han et al., 2014; Li et al., 2015) and both are induced by neutrophils (Campbell et al., 2014; Coffelt et al., 2016) , future studies should test the role of TAN-induced ROS and hypoxia in this phenomenon.
Multiple studies have indicated that relapsed LADC after targeted therapy or chemotherapy can transition to LSCC, although the mechanisms are still poorly understood (Hou et al., 2016) . Understanding the heterogeneity and plasticity of the TIME and how tumor genotype shapes the TIME is crucial for effective therapy. Here we find that the genetic mechanisms that regulate adeno-to-squamous transdifferentiation also shape the TIME and that, in turn, immune cells can impact tumor phenotype. Future studies are warranted for determining how TANs and other immune cell types evolve during tumor transdifferentiation and how these fluctuations might affect response to immunotherapy.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS Mice
Mice were housed in an environmentally controlled room and all experiments were performed in accordance with University of Utah's Institutional Animal Care and Use Committee. Lkb1 fl/fl mice were purchased from The Jackson Laboratory. Mice harboring Kras LSL-G12D/+ (Jackson et al., 2001) , Trp53 fl/fl (Jonkers et al., 2001) , Nkx2-1 fl/fl (Kusakabe et al., 2006) , Kras FSF-G12D/+ (Young et al., 2011) , Trp53 FRT/FRT (Lee et al., 2012) , Rosa26 FSF-CreERT2 (Schö nhuber et al., 2014) , Pten fl/fl (Zheng et al., 2008 ) alleles have been previously described. Sox2 LSL/LSL mice were generated using a standard approach: the full-length cDNA of Sox2 was placed in the Rosa26 targeting vector behind a floxed stop and neomycin resistance cassette followed by eGfp on an internal ribosomal entry site. The targeting vector for the Rosa26-Lox-Stop-Lox-Sox2-IRES-GFP allele was electroporated into mouse R1 embryonic stem cells and the G418-resistant clones were screened by long-range PCR for the correct 5 0 and 3 0 insertion. The correct clones were then subjected to Southern blot analysis to identify insertion number and size. Cells from one clone with a confirmed target were microinjected into C57BL/6 blastocysts to generate chimeric mice. The chimeric mice were mated to C57BL/6 females and their agouti offspring were tested by PCR to confirm germline transmission of the conditional allele. All Rosa26 targeted mice were genotyped with the following primers using tail-tip derived DNA: Forward 5 0 -GTTATCAGTAAGGGAGCTGCAGTGG-3 0 , Reverse-targeted 5 0 -AA GACCGCGAAGAGTTTGTCCTC-3 0 , Reverse-wild-type 5 0 -GGCGGATCACAAGCAATAATAACC-3 0 . These primers yield a 300 base pair (bp) band for the targeted locus and a 415 bp band for wild-type locus. The PCR conditions were set to 95 C for 30 s, 59 C for 45 s and 72 C for 30 s, for 30 cycles. At 6-8 weeks of age, anesthetized mice were infected with 10 7 -10 8 plaque-forming units of Ad5-CMV-Cre viruses (University of Iowa Cat#VVC-U of Iowa-5) or Ad5-CMV-Flp (University of Iowa Cat#VVC-U of Iowa-530) or with $10 7 infectious units/ml of Lenti-Sox2-Cre, Lenti-Gfp-Cre, or Lenti-Cxcl5-Cre lentiviruses by intranasal or intratracheal instillation. Viruses were administered in a Biosafety Level 2+ room according to Institutional Biosafety Committee guidelines. At six weeks post-infection, KPN mice were treated with vehicle or tamoxifen for four weeks to induce Nkx2-1 deletion. Tamoxifen (Sigma Cat#T5648) was dissolved in corn oil with a final concentration of 20 mg/ml and administered at a dose of 120 mg/kg per day for 6 days. Additionally, mice were fed ad libitum with 500 mg/kg tamoxifen-supplemented chow (Envigo Cat#TD.130858) in place of standard chow for the duration of the experiment. Both male and female mice were equally segregated for all experiments.
MEFs
MEFs were isolated from SL embryos on day E13.5 and cultured in DMEM, 10% FBS, 1% Pen/Strep, 1% L-Glutamine, and 50 mM 2-Mercaptoethanol. Dissected tissues were incubated in 5 mL 2X trypsin at 37 C for 5 minutes. Single cell suspension was collected and transferred into 50 mL tubes with 25 mL pre-warmed MEF medium. After centrifugation at 1500 RPM for 5 minutes, pelleted cells were resuspended in 10 mL MEF media and transferred into tissue culture plates. Media was replaced 24 hours later. positive cell score was calculated as: tumors with less than 1% positive cells were score = 0; tumors with positive cells between 1% -3% were score = 1; tumors with positive cells between 3% -6% were score = 2; tumors with more than 6% positive cells were score = 3.
Immunoblot
Total protein lysates were prepared as previously described, separated via SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked for 1 hr in 5% milk or 5% BSA, followed by overnight incubation with primary antibodies at 4 C. Membranes were washed for 3 3 15 min at room temperature in TBS-T. Mouse and rabbit HRP-conjugated secondary antibodies (Jackson ImmunoResearch, 1:10,000) were incubated for 1 hr at room temperature followed by washing 3 3 15 min at room temperature in TBS-T. For detection, membranes were exposed to Advansta WesternBright ECL HRP Substrate Kit (VWR #490005-020) and detected on Hyblot CL film (Denville Scientific Inc). Primary antibodies: SOX2 (Millipore Cat#MAB4423) 1:2000; ACTIN (Sigma Cat#A2066) 1:10,000; NKX2-1 (Abcam Cat#ab76013) 1:2000; CXCL5/6 (Abcam Cat#ab198505) 1:1000; HSP90 (Cell Signaling Cat#4877) 1:1000. ACTIN or HSP90 were used as loading controls. Densitometry analyses were performed with Image Studio Lite software. The signal value of each sample was normalized by its loading control value. Then the normalized value of a control sample was set to 1 arbitrary unit while each test sample value was presented as a relative intensity compared to control.
RNA Isolation and RNA-Sequencing 5 mm serial sections of FFPE tissue were stained with H&E and Aniline blue. H&E stained slides were used to confirm histology of tumors and guide bordering consecutive serial sections of Aniline blue stained tissue samples. Bordered tissue samples were microdissected using sterile disposable scalpels and razor blades with the assistance of a dissection scope. 10 -14 pieces of each sample isolated from serial sections were pooled in a microcentrifuge tube containing 100% ethanol. RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Cat#AM1975) was used to isolate RNA from FFPE tissues according to the manufacturer's protocol. RNA samples were quantified using NanoDrop 8000 and Qubit RNA HS Assay. RNA integrity numbers were calculated on Agilent HS RNA ScreenTape. RNA was subjected to library construction with the Illumina TruSeq Stranded mRNA Sample Preparation Kit (Cat#RS-122-2101, RS-122-2102) according to manufacturer's protocol. Chemically denatured sequencing libraries (25 pM) are applied to an Illumina HiSeq v4 single read flow cell using an Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers with reagents from an Illumina HiSeq SR Cluster Kit v4-cBot . Following the transfer of the flowcell to an Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50-cycle single-read sequence run was performed using HiSeq SBS Kit v4 sequencing reagents . Mouse mm10 annotations (Ensembl build 82) were used in the RSEM (v1.2.12) utility rsem-prepare-reference to create bowtie (v1.0.1) indices. Gene expression was determined using the RSEM utility rsem-calculate-expression with the forward strand probability set to zero. Differential expression was determined using EBSeq (v1.4.0) using 'MedianNorm' function to calculate size factors and setting 'maxround' to 10. To adjust for transcript length, fragments per kilobase per million reads (FPKM) were calculated for all genes and log2-transformed after addition of a small constant (0.01).
Chromatin Immunoprecipitation Sequencing (ChIP-seq) 20 million cells per ChIP were cross-linked in 1% formaldehyde for 10 min at room temperature. Crosslinking was stopped with 125 mM glycine and nuclei were extracted. Alternatively, flash-frozen tumors were directly used. Chromatin was sonicated using an Epishear Probe Sonicator (Active Motif) for 4 min at 40% power. SOX2 antibody (R&D Systems Cat#AF2018) was used for IP and an input sample for each cell line served as the control. Libraries were sequenced on an Illumina HiSeq 2500 as single-end 50 bp reads to a minimum depth of 35 million reads per sample. Reads were aligned to the mm10 build of the mouse genome with bowtie using the following parameters: -m 1 -t-best -q -S -l 32 -e 80 -n 2. Peaks were called with MACS2 using a p value cutoff of 10 À10 and the mfold parameter bounded between 15 and 100. For visualization, MACS2 produced bedgraphs with the -B and -SPMR options. The Integrative Genomics Viewer (IGV) software was used to visualize binding sites. NKX2-1 ChIPseq data from K adenocarcinomas and exon array data comparing K and KN tumors were obtained from previously published data (Snyder et al., 2013) . Mice were euthanized to harvest tissue. Tumor or normal lung tissue was excised and kept in cold PBS with a matching tissue piece collected for histology. Tissue sample was chopped into smaller pieces mechanically and further dissociated with 1 mL digestion media at 37 C for 30 min. Digestion reaction was stopped by adding 0.5 mL quench media. Digested tissue was passed through 20-gauge needle syringe multiple times to aid dissociation. Digested samples were passed through a 100 mm cell strainer and single cells were collected into a round-bottom polystyrene tube. Cells were pelleted by centrifugation at 1500 rpm at 4 C for 5 min. Cells were resuspended in 0.5 mL ACK (Ammonium-Chloride-Potassium) lysing buffer and incubated at 37 C for 3 min to lyse erythrocytes. The lysis reaction was stopped by addition of 4.5 mL cold PBS. Blood was collected via cardiac puncture with a 1 mL syringe with a 23-gauge needle that was pre-coated with PBS + EDTA (5 mM final concentration). Cells were pelleted by centrifugation at 1500 rpm at 4 C for 5 min and processed as described above for tumor cells. Cell number and viability were measured by Countess II FL Automated Cell Counter (Thermo Fisher Cat#AMQAX1000).
For cell surface staining, single cell suspensions were stained with fluorescent conjugated antibodies for 30 min at 4 C in dark. Cells were then washed with and resuspended in FACS buffer. DAPI was used for dead cell exclusion. For intracellular staining, cells were stained with a fixable viability dye simultaneously with cell surface staining as explained above. After washing with FACS buffer, cells were resuspended in residual buffer (100 ml) and fixed with the addition of 100 ml fixation buffer for 30 min at 4 C in dark. Cells were then washed in 2 mL of 1X permeabilization buffer two times and resuspended in 200 ml permeabilization buffer. Cells were stained with unconjugated primary antibody for intracellular antigen for 30 min at 4 C in dark. Cells were then washed with permeabilization buffer and stained with fluorescent conjugated secondary antibody for 30 min at 4 C in dark. Cells were washed in permeabilization buffer and FACS buffer, followed by resuspension in FACS buffer. Data acquisition was performed with BD FACSAria Cell Sorter (BD Biosciences) running BD FACSDiva 8.0.2 software and analyzed with FlowJo 10.2 (FlowJo, LLC, Ashland, OR).
Buffers and reagents include: Digestion media: 4200 ml HBSS-free (Thermo Fisher Cat#14175), 600 ml trypsin-EDTA (0.25%) (Thermo Fisher Cat#25200-072), 600 ml collagenase type 4 (Worthington Biochemical Cat#LS004186) from 10 mg/ml stock prepared in HBSS with calcium and magnesium (Thermo Fisher Cat#14025), 600 ml dispase (Worthington Biochemical Cat#LS02100). Quench solution: 7.2 mL Leibovitz's L15 media (Thermo Fisher Cat#11415-064), 800 ml FBS (Sigma Cat#12303C), 30 ml DNase (Sigma Cat#D4527) at 5 mg/ml in HBSS-free media. ACK (Ammonium-Chloride-Potassium) lysing buffer: (Thermo Fisher Cat#A10492). and PBN population (n = blood from 2 SNL mice). Without any freezing or fixation steps, the single cell populations were immediately processed. Cell suspensions were partitioned into an emulsion of nanoliter-sized droplets using a 10X Genomics Chromium Single Cell Controller and RNA sequencing libraries were constructed using the Chromium Single Cell 3 0 Reagent Kit v2 (10X Genomics Cat#PN-120237). Briefly, droplets contained individual cells, reverse transcription reagents and a gel bead loaded with poly(dT) primers that include a 16 base cell barcode and a 10 base unique molecular index (UMI). Lysis of the cells and gel bead enables priming and reverse transcription of poly-A RNA to generate barcoded cDNA molecules. Libraries were constructed by End Repair, A-Tailing, Adaptor Ligation and PCR amplification of the cDNA molecules. Purified cDNA libraries were qualified on an Agilent Technologies 2200 TapeStation using a D1000 ScreenTape assay . The molarity of adaptormodified molecules was defined by quantitative PCR using the Kapa Biosystems Kapa Library Quant Kit (Kapa Biosystems Cat#KK4824). Individual libraries were normalized to 10 nM and equal volumes were pooled in preparation for Illumina sequence analysis. Sequencing libraries (25 pM) were chemically denatured and applied to an Illumina HiSeq v4 paired end flow cell using an Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers with reagents from an Illumina HiSeq PE Cluster Kit v4-cBot . Following transfer of the flowcell to an Illumina HiSeq 2500 instrument (HCS v2.2.38 and RTA v1.18 .61), a 125 3 125 cycle paired-end sequence run was performed using HiSeq SBS Kit v4 sequencing reagents (Illumina Cat#FC-401-4003).
Evaluation of Neutrophil Morphology
Lung tumors from AdCre-infected SNL and normal lung tissues from uninfected SNL control mice were processed for single cell suspension and single cell samples were stained for neutrophil markers as described in the ''Flow Cytometry'' methods section. A BD FACSAria III was used for FACS. Dead cells and debris were excluded by gating for FSC, SSC and DAPI. CD45 was used as a leukocyte marker and CD11B was used as a myeloid marker. Neutrophils were defined as CD45 + CD11B + GR1
+/hi . Isolated cells were pelleted on slides with centrifugation at 1,500 rpm for 30 min in a Shandon Cytospin 3 (Shandon Lipshaw, Inc., Pittsburgh, PA). The cells were then stained with Diff-Quik stain and analyzed by light microscopy at 40X.
Ex vivo ROS Activity
Lung tumors, healthy lung tissues, and peripheral blood samples were processed to generate single cell suspensions and cells were stained for cell surface markers with fluorescent conjugated antibodies as detailed in the ''Flow Cytometry'' methods. Following antibody incubation, cells were washed and resuspended in PBS-EGG buffer. Dihydrorhodamine 123 (Thermo Fisher Cat#D23806) was added to cells in PBS-EGG buffer with a final concentration of 0.5 mM and cells were incubated at 37 C for 30 min. Cells were then washed and resuspended in FACS buffer and were immediately analyzed in the FITC channel for ROS indicator. Cells treated with For single cell RNA-seq analysis, 10x Genomics' Cell Ranger software (v2.1.1) executed the primary data analysis, including but not limited to: (I) demultiplexing cDNA libraries into FASTQ files; (II) aligning reads to the mouse genome (Cell Ranger mm10 custom reference v2.1.0); (III) barcode processing for estimation of gene-cell UMI counts; (IV) QC reporting; (V) clustering, dimension reduction, and differential gene expression analysis using default parameter inputs (see https://support.10xgenomics.com/single-cellgene-expression/software/pipelines/latest/using/ reanalyze). For further details of the Cell Ranger data processing, see https:// support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/algorithms/ overview. Secondary data analysis was evaluated with 10x Genomics' Cell Loupe Browser. For TANs (n = 519 cells), the estimated mean reads per cell were 99,194 with 86.3% saturation density. For PBNs (n = 1,744 cells), the estimated mean reads per cell were 33,786 with 61.8% saturation density. For analysis, genes with low average UMI count were filtered out.
QUANTIFICATION AND STATISTICAL ANALYSIS
GraphPad Prism 7 was used to perform statistical analyses. Tumor-free survival analyses were analyzed using log-rank (Mantel-Cox) test. Error bars represent mean ± SEM unless otherwise indicated. For the statistical analysis of the IHC scores and tumor penetrance, column analysis was performed by Student's unpaired t test with p value < 0.05 considered significant. For box-and-whisker plots, boxes show 25th, median and 75th quartile; whiskers extend to 1.5x interquartile range above/below the highest/lowest quartiles. All statistical details are further described in respective figure legends. Additional statistical methods related to bioinformatic analyses can be found in Bioinformatic Analyses under Method Details. No statistical methods were used to predetermine sample sizes. Please see details of IHC quantifications in Immunohistochemistry section and western blot quantifications in Immunoblot section of Method Details.
DATA AND SOFTWARE AVAILABILITY Data Resources
Tissue RNA-sequencing data, single-cell RNA-sequencing data, and SOX2 chromatin immunoprecipitation sequencing data in this study have been deposited in the NCBI GEO (GEO: GSE118252).
